Literature DB >> 29706292

A novel adjuvant G3 induces both Th1 and Th2 related immune responses in mice after immunization with a trivalent inactivated split-virion influenza vaccine.

Bernt Hjertner1, Theresa Bengtsson2, Bror Morein3, Staffan Paulie4, Caroline Fossum5.   

Abstract

A preferred adjuvant should promote both Th1 and Th2 responses. However, most adjuvants in common use are biased towards a Th2-driven response. Therefore, the ability of a novel saponin-based adjuvant G3 to inducing balanced Th1 and Th2 responses in BALB/c mice immunized with a split trivalent seasonal influenza vaccine was evaluated in comparison to that of the adjuvant Al(OH)3. Clear differences in the IgG profiles induced by G3, Al(OH)3 or non-adjuvanted vaccine were recorded. Both adjuvants enhanced high and similar levels of the Th2 associated IgG1 subtype compared to mice given vaccine alone. Only G3 enhanced the IgG2a subclass reflecting a Th1 response, whereas Al(OH)3 even abrogated the IgG2a production. Accordingly, G3 enhanced the production of IL-2 and IFN-γ and also of IL-2/IFN-γ double secreting cells, emphasizing the strong Th1 driving effect of G3. Only Al(OH)3 increased splenocyte production of IL-17. Taken together, the results indicate a strong propensity for G3 to induce both Th1 and Th2 driven immune responses.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Adjuvant; Cytokine production; Influenza; Th1/Th2

Mesh:

Substances:

Year:  2018        PMID: 29706292     DOI: 10.1016/j.vaccine.2018.04.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  IFITM3 affects the level of antibody response after influenza vaccination.

Authors:  Na Lei; Yan Li; Qiang Sun; Jian Lu; Jianfang Zhou; Zi Li; Liqi Liu; Junfeng Guo; Kun Qin; Haibin Wang; Jianhong Zhao; Chong Li; Lingli Sun; Dayan Wang; Zhendong Zhao; Yuelong Shu
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

2.  Combination of STING Pathway Agonist With Saponin Is an Effective Adjuvant in Immunosenescent Mice.

Authors:  Elena V Vassilieva; Dahnide W Taylor; Richard W Compans
Journal:  Front Immunol       Date:  2019-12-23       Impact factor: 7.561

3.  Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine.

Authors:  Lu Lu; Carol Ho-Yan Fong; Anna Jinxia Zhang; Wai-Lan Wu; Iris Can Li; Andrew Chak-Yiu Lee; Thrimendra Kaushika Dissanayake; Linlei Chen; Ivan Fan-Ngai Hung; Kwok-Hung Chan; Hin Chu; Kin-Hang Kok; Kwok-Yung Yuen; Kelvin Kai-Wang To
Journal:  Vaccines (Basel)       Date:  2020-12-11

4.  Antioxidant and Inflammatory Effects of Nelumbo nucifera Gaertn. Leaves.

Authors:  Chong Li; Yongpeng He; Yue Yang; Yuting Gou; Shuting Li; Rui Wang; Shi Zeng; Xin Zhao
Journal:  Oxid Med Cell Longev       Date:  2021-12-28       Impact factor: 6.543

5.  Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant.

Authors:  Yucheol Cheong; Minjin Kim; Jina Ahn; Hana Oh; Jongkwan Lim; Wonil Chae; Seung Won Yang; Min Seok Kim; Ji Eun Yu; Sanguine Byun; Yo Han Jang; Baik Lin Seong
Journal:  Front Immunol       Date:  2021-11-12       Impact factor: 7.561

6.  A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine.

Authors:  Huapeng Feng; Ruolin Sun; Guanru Song; Shunfan Zhu; Zhenyu Nie; Liming Lin; Ruonan Yi; Shixiang Wu; Genzhu Wang; Yulong He; Siquan Wang; Pei Wang; Li Wu; Jianhong Shu
Journal:  Viruses       Date:  2022-05-28       Impact factor: 5.818

7.  The adjuvant G3 promotes a Th1 polarizing innate immune response in equine PBMC.

Authors:  Stina Hellman; Bernt Hjertner; Bror Morein; Caroline Fossum
Journal:  Vet Res       Date:  2018-10-22       Impact factor: 3.683

8.  Cytokine responses to various larval stages of equine strongyles and modulatory effects of the adjuvant G3 in vitro.

Authors:  Stina Hellman; Eva Tydén; Bernt Hjertner; Frida Nilsfors; Kefei Hu; Bror Morein; Caroline Fossum
Journal:  Parasite Immunol       Date:  2020-10-04       Impact factor: 2.280

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.